Hasta la próxima

Auto reproducción

The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

2 vistas • 07/18/23
Compartir
Empotrar
administrator
administrator
Suscriptores
0

Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

Mostrar más
0 Comentarios sort Ordenar por
Comentarios de Facebook

Hasta la próxima

Auto reproducción